Skip to main content

Does Caplyta cause weight gain?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 31, 2025.

Official answer

by Drugs.com

Caplyta (lumateperone) is not typically associated with weight gain, a common concern with some antipsychotic medications. It is an atypical antipsychotic used to treat schizophrenia and bipolar depression in adults.

Clinical Trial Results on Weight Gain

A review of multiple clinical trials found that weight gain in patients treated with Caplyta was comparable to those who received a placebo.

A separate long-term study observed patients who switched from standard antipsychotic treatments to Caplyta for one year. Results showed:

  • A significant reduction in mean body weight (-2.1 kg, P <0.001).
  • Decreases in body mass index (BMI) and waist circumference over time.

These findings suggest that Caplyta may be a suitable option for patients concerned about weight gain with antipsychotic treatment. Always consult your healthcare provider to discuss potential side effects and the best treatment approach for your condition.

References

Read next

What is the mechanism of action for Caplyta?

Caplyta (lumateperone) is thought to work by changing the activity of certain chemicals called neurotransmitters in the brain. These neurotransmitters include dopamine, glutamate, and serotonin. Continue reading

Caplyta savings card: Do I qualify and how much can I save?

To be eligible for the Caplyta Savings Card, you must be 18 years of age or older, have a prescription for Caplyta, and have private commercial insurance. It cannot be used with federal or state health programs. If you qualify, you may pay as little as $0 for the first two fills of a 30-day supply of Caplyta, up to the maximum lifetime benefit which is based on the current list price of a 30-day supply. After that, you pay $15 for fills up to a 90-day supply (maximum benefit $600). Continue reading

How long does it take Caplyta to work?

Patient with schizophrenia started to show improved Positive and Negative Syndrome Scale (PANSS) total scores after one week of treatment with Caplyta (lumateperone), according to the results of a phase III trial. PANSS is a scale used to measure the severity of schizophrenia symptoms. Symptoms continue to improve the longer you take the drug. Continue reading

Related medical questions

Drug information

Related support groups